We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

126 hedge funds and large institutions have $759M invested in Neurocrine Biosciences in 2013 Q2 according to their latest regulatory filings, with 126 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more call options, than puts

Call options by funds: $14.3M | Put options by funds: $9.91M

Holders
126
Holders Change
+126
Holders Change %
–
% of All Funds
4.11%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.07%
New
126
Increased
–
Reduced
–
Closed
–
Calls
$14.3M
Puts
$9.91M
Net Calls
+$4.43M
Net Calls Change
+$4.43M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
26
Wellington Management Group
Massachusetts
$5.76M +$5.29M +430,403 New
Invesco
27
Invesco
Georgia
$5.23M +$4.81M +391,160 New
Lord, Abbett & Co
28
Lord, Abbett & Co
New Jersey
$5.04M +$4.63M +376,503 New
Goldman Sachs
29
Goldman Sachs
New York
$4.72M +$4.33M +352,678 New
TCIM
30
TIAA CREF Investment Management
New York
$3.93M +$3.61M +293,843 New
MG
31
Meditor Group
Bermuda
$3.61M +$3.32M +270,000 New
Geode Capital Management
32
Geode Capital Management
Massachusetts
$3.35M +$3.07M +250,022 New
AAMU
33
Amundi Asset Management US
Massachusetts
$3.32M +$3.05M +248,000 New
ACH
34
ArrowMark Colorado Holdings
Colorado
$3.31M +$3.04M +247,567 New
BNP Paribas Asset Management
35
BNP Paribas Asset Management
France
$3.22M +$2.96M +240,577 New
Aviva
36
Aviva
United Kingdom
$2.74M +$2.51M +204,519 New
SCM
37
Sigma Capital Management
Connecticut
$2.68M +$2.46M +200,000 New
SFM
38
Soros Fund Management
New York
$2.68M +$2.46M +200,000 New
AQR Capital Management
39
AQR Capital Management
Connecticut
$2.51M +$2.3M +187,400 New
EI
40
EAM Investors
California
$2.42M +$2.22M +180,478 New
BIM
41
BlackRock Investment Management
Delaware
$2.38M +$2.18M +177,745 New
JP Morgan Chase
42
JP Morgan Chase
New York
$2.36M +$2.16M +176,077 New
Jane Street
43
Jane Street
New York
$2.27M +$2.09M +169,991 New
RFC
44
Russell Frank Company
Washington
$2.2M +$2.02M +164,490 New
Charles Schwab
45
Charles Schwab
California
$2.15M +$1.94M +158,017 New
PI
46
Putnam Investments
Massachusetts
$2.12M +$1.94M +158,300 New
LCG
47
Lisanti Capital Growth
New York
$2.02M +$1.77M +144,455 New
DIA
48
Denver Investment Advisors
Colorado
$2.01M +$1.84M +150,064 New
WMSA
49
Weiss Multi-Strategy Advisers
New York
$2.01M +$1.84M +150,000 New
TD Asset Management
50
TD Asset Management
Ontario, Canada
$1.95M +$1.79M +145,600 New
1
2
3 4 5

NBIX Hedge Fund Activity: Q2 2013 in Review

126 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2013, worth a combined $759M.

Buyers outnumbered sellers: 126 funds opened new NBIX positions and 0 closed out — a net gain of 126 holders — while 0 added to existing stakes and 0 trimmed.

  • 126 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $759M of Neurocrine Biosciences stock for Q2 2013.
  • 126 funds opened new Neurocrine Biosciences positions in Q2 2013 and 0 closed out, a net change of +126 holders.

Based on aggregated 13F filings for Q2 2013.